| Objective：To observe the clinical efficacy of botulinum toxin type A (BTX-A) for trigeminal neuralgia. Methods：Forty-seven cases of trigeminal neuralgia were randomly divided into two groups, receiving Carbamazeping tabs (control group, A), and subcutaneous injection of BTX-A (therapy group, B), respectively. The onset of trigeminal neuralgia, severity of trigeminal neuralgia, as well as side effects in patients with trigeminal neuralgia were recorded by the use of questionnaire, and compared before and 6 months after treatment. Results：The short form McGill Pain Questionnaire and Quality of Life Scale scores were significantly different before and 1, 3 and 6 months after treatment in both two groups. There was significant difference in the short form McGill Pain Questionnaire and Quality of Life Scale scores between groups A and B 1, 3 and 6 months after treatment (P<0.05). Conclusion: BTX-A has therapeutic effects on trigeminal neuralgia with few side effects. |
